Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...
New York, USA, October 22nd, 2025, FinanceWire BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company ...
Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...
Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a ...
Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final ...
Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...
Tiziana Life Sciences (NASDAQ:TLSA) recently announced that it submitted its IND of fully human anti-CD3 monoclonal antibody foralumab to begin a phase 2 study for the treatment of patients with ...
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email.
Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback